Check-Cap Ltd. - Asset Resilience Ratio
Check-Cap Ltd. (MBAI) has an Asset Resilience Ratio of 2.90% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read MBAI total debt and obligations for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2021–2025)
This chart shows how Check-Cap Ltd.'s Asset Resilience Ratio has changed over time. See Check-Cap Ltd. shareholders equity for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down Check-Cap Ltd.'s liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Check-Cap Ltd. market cap and net worth.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $217.00K | 2.9% |
| Total Liquid Assets | $217.00K | 2.90% |
Asset Resilience Insights
- Limited Liquidity: Check-Cap Ltd. maintains only 2.90% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Check-Cap Ltd. Industry Peers by Asset Resilience Ratio
Compare Check-Cap Ltd.'s asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Sonic Healthcare Ltd
AU:SHL |
Diagnostics & Research | 0.13% |
|
Inoviq Ltd
AU:IIQ |
Diagnostics & Research | 56.29% |
|
RHYTHM Biosciences Ltd
AU:RHY |
Diagnostics & Research | 2.74% |
|
Bcal Diagnostics Ltd
AU:BDX |
Diagnostics & Research | 0.00% |
|
Genetic Signatures Ltd
AU:GSS |
Diagnostics & Research | 60.91% |
|
Integral Diagnostics Ltd
AU:IDX |
Diagnostics & Research | 0.03% |
|
Australian Clinical Labs Ltd
AU:ACL |
Diagnostics & Research | 4.11% |
|
Monash Ivf Group Ltd
AU:MVF |
Diagnostics & Research | 1.60% |
Annual Asset Resilience Ratio for Check-Cap Ltd. (2021–2025)
The table below shows the annual Asset Resilience Ratio data for Check-Cap Ltd..
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 2.90% | $217.00K | $7.49 Million | -60.71pp |
| 2023-12-31 | 63.60% | $15.91 Million | $25.02 Million | -19.16pp |
| 2022-12-31 | 82.76% | $37.61 Million | $45.44 Million | +37.66pp |
| 2021-12-31 | 45.10% | $25.10 Million | $55.66 Million | -- |
About Check-Cap Ltd.
Check-Cap Ltd., a clinical stage medical diagnostics company, focuses on capsule-based screening technology products. Check-Cap Ltd. was incorporated in 2004 and is based in Isfiya, Israel.